Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: A two-center, matched case-control study

Gennaro De Pascale, Gennaro Martucci, Luca Montini, Giovanna Panarello, Salvatore Lucio Cutuli, Daniele Di Carlo, Valentina Di Gravio, Roberta Di Stefano, Guido Capitanio, Maria Sole Vallecoccia, Piera Polidori, Teresa Spanu, Antonio Arcadipane, Massimo Antonelli

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Recent reports have suggested the efficacy of a double carbapenem (DC) combination, including ertapenem, for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-Kp) infections. We aimed to evaluate the clinical impact of such a regimen in critically ill patients. Methods: This case-control (1:2), observational, two-center study involved critically ill adults with a microbiologically documented CR-Kp invasive infection treated with the DC regimen matched with those receiving a standard treatment (ST) (i.e., colistin, tigecycline, or gentamicin). Results: The primary end point was 28-day mortality. Secondary outcomes were clinical cure, microbiological eradication, duration of mechanical ventilation and of vasopressors, and 90-day mortality. Forty-eight patients treated with DC were matched with 96 controls. Occurrence of septic shock at infection and high procalcitonin levels were significantly more frequent in patients receiving DC treatment (p < 0.01). The 28-day mortality was significantly higher in patients receiving ST compared with the DC group (47.9% vs 29.2%, p = 0.04). Similarly, clinical cure and microbiological eradication were significantly higher when DC was used in patients infected with CR-Kp strains resistant to colistin (13/20 (65%) vs 10/32 (31.3%), p = 0.03 and 11/19 (57.9%) vs 7/27 (25.9%), p = 0.04, respectively). In the logistic regression and multivariate Cox-regression models, the DC regimen was associated with a reduction in 28-day mortality (OR 0.33, 95% CI 0.13-0.87 and OR 0.43, 95% CI 0.23-0.79, respectively). Conclusions: Improved 28-day mortality was associated with the DC regimen compared with ST for severe CR-Kp infections. A randomized trial is needed to confirm these observational results. Trial registration: ClinicalTrials.gov NCT03094494. Registered 28 March 2017.

Original languageEnglish
Article number173
JournalCritical Care
Volume21
Issue number1
DOIs
Publication statusPublished - Jul 5 2017

Fingerprint

Klebsiella Infections
Carbapenems
Klebsiella pneumoniae
Case-Control Studies
Therapeutics
Mortality
Colistin
Critical Illness
carbapenemase
Calcitonin
Septic Shock
Infection
Gentamicins
Artificial Respiration
Proportional Hazards Models

Keywords

  • Critically ill patients
  • Double carbapenem
  • Ertapenem
  • Infections
  • Klebsiella pneumoniae
  • Meropenem
  • Multidrug-resistant bacteria

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections : A two-center, matched case-control study. / De Pascale, Gennaro; Martucci, Gennaro; Montini, Luca; Panarello, Giovanna; Cutuli, Salvatore Lucio; Di Carlo, Daniele; Di Gravio, Valentina; Di Stefano, Roberta; Capitanio, Guido; Vallecoccia, Maria Sole; Polidori, Piera; Spanu, Teresa; Arcadipane, Antonio; Antonelli, Massimo.

In: Critical Care, Vol. 21, No. 1, 173, 05.07.2017.

Research output: Contribution to journalArticle

De Pascale, Gennaro ; Martucci, Gennaro ; Montini, Luca ; Panarello, Giovanna ; Cutuli, Salvatore Lucio ; Di Carlo, Daniele ; Di Gravio, Valentina ; Di Stefano, Roberta ; Capitanio, Guido ; Vallecoccia, Maria Sole ; Polidori, Piera ; Spanu, Teresa ; Arcadipane, Antonio ; Antonelli, Massimo. / Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections : A two-center, matched case-control study. In: Critical Care. 2017 ; Vol. 21, No. 1.
@article{54615d4d21ec4b07b71d65e0a743b053,
title = "Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: A two-center, matched case-control study",
abstract = "Background: Recent reports have suggested the efficacy of a double carbapenem (DC) combination, including ertapenem, for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-Kp) infections. We aimed to evaluate the clinical impact of such a regimen in critically ill patients. Methods: This case-control (1:2), observational, two-center study involved critically ill adults with a microbiologically documented CR-Kp invasive infection treated with the DC regimen matched with those receiving a standard treatment (ST) (i.e., colistin, tigecycline, or gentamicin). Results: The primary end point was 28-day mortality. Secondary outcomes were clinical cure, microbiological eradication, duration of mechanical ventilation and of vasopressors, and 90-day mortality. Forty-eight patients treated with DC were matched with 96 controls. Occurrence of septic shock at infection and high procalcitonin levels were significantly more frequent in patients receiving DC treatment (p < 0.01). The 28-day mortality was significantly higher in patients receiving ST compared with the DC group (47.9{\%} vs 29.2{\%}, p = 0.04). Similarly, clinical cure and microbiological eradication were significantly higher when DC was used in patients infected with CR-Kp strains resistant to colistin (13/20 (65{\%}) vs 10/32 (31.3{\%}), p = 0.03 and 11/19 (57.9{\%}) vs 7/27 (25.9{\%}), p = 0.04, respectively). In the logistic regression and multivariate Cox-regression models, the DC regimen was associated with a reduction in 28-day mortality (OR 0.33, 95{\%} CI 0.13-0.87 and OR 0.43, 95{\%} CI 0.23-0.79, respectively). Conclusions: Improved 28-day mortality was associated with the DC regimen compared with ST for severe CR-Kp infections. A randomized trial is needed to confirm these observational results. Trial registration: ClinicalTrials.gov NCT03094494. Registered 28 March 2017.",
keywords = "Critically ill patients, Double carbapenem, Ertapenem, Infections, Klebsiella pneumoniae, Meropenem, Multidrug-resistant bacteria",
author = "{De Pascale}, Gennaro and Gennaro Martucci and Luca Montini and Giovanna Panarello and Cutuli, {Salvatore Lucio} and {Di Carlo}, Daniele and {Di Gravio}, Valentina and {Di Stefano}, Roberta and Guido Capitanio and Vallecoccia, {Maria Sole} and Piera Polidori and Teresa Spanu and Antonio Arcadipane and Massimo Antonelli",
year = "2017",
month = "7",
day = "5",
doi = "10.1186/s13054-017-1769-z",
language = "English",
volume = "21",
journal = "Critical Care",
issn = "1466-609X",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections

T2 - A two-center, matched case-control study

AU - De Pascale, Gennaro

AU - Martucci, Gennaro

AU - Montini, Luca

AU - Panarello, Giovanna

AU - Cutuli, Salvatore Lucio

AU - Di Carlo, Daniele

AU - Di Gravio, Valentina

AU - Di Stefano, Roberta

AU - Capitanio, Guido

AU - Vallecoccia, Maria Sole

AU - Polidori, Piera

AU - Spanu, Teresa

AU - Arcadipane, Antonio

AU - Antonelli, Massimo

PY - 2017/7/5

Y1 - 2017/7/5

N2 - Background: Recent reports have suggested the efficacy of a double carbapenem (DC) combination, including ertapenem, for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-Kp) infections. We aimed to evaluate the clinical impact of such a regimen in critically ill patients. Methods: This case-control (1:2), observational, two-center study involved critically ill adults with a microbiologically documented CR-Kp invasive infection treated with the DC regimen matched with those receiving a standard treatment (ST) (i.e., colistin, tigecycline, or gentamicin). Results: The primary end point was 28-day mortality. Secondary outcomes were clinical cure, microbiological eradication, duration of mechanical ventilation and of vasopressors, and 90-day mortality. Forty-eight patients treated with DC were matched with 96 controls. Occurrence of septic shock at infection and high procalcitonin levels were significantly more frequent in patients receiving DC treatment (p < 0.01). The 28-day mortality was significantly higher in patients receiving ST compared with the DC group (47.9% vs 29.2%, p = 0.04). Similarly, clinical cure and microbiological eradication were significantly higher when DC was used in patients infected with CR-Kp strains resistant to colistin (13/20 (65%) vs 10/32 (31.3%), p = 0.03 and 11/19 (57.9%) vs 7/27 (25.9%), p = 0.04, respectively). In the logistic regression and multivariate Cox-regression models, the DC regimen was associated with a reduction in 28-day mortality (OR 0.33, 95% CI 0.13-0.87 and OR 0.43, 95% CI 0.23-0.79, respectively). Conclusions: Improved 28-day mortality was associated with the DC regimen compared with ST for severe CR-Kp infections. A randomized trial is needed to confirm these observational results. Trial registration: ClinicalTrials.gov NCT03094494. Registered 28 March 2017.

AB - Background: Recent reports have suggested the efficacy of a double carbapenem (DC) combination, including ertapenem, for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-Kp) infections. We aimed to evaluate the clinical impact of such a regimen in critically ill patients. Methods: This case-control (1:2), observational, two-center study involved critically ill adults with a microbiologically documented CR-Kp invasive infection treated with the DC regimen matched with those receiving a standard treatment (ST) (i.e., colistin, tigecycline, or gentamicin). Results: The primary end point was 28-day mortality. Secondary outcomes were clinical cure, microbiological eradication, duration of mechanical ventilation and of vasopressors, and 90-day mortality. Forty-eight patients treated with DC were matched with 96 controls. Occurrence of septic shock at infection and high procalcitonin levels were significantly more frequent in patients receiving DC treatment (p < 0.01). The 28-day mortality was significantly higher in patients receiving ST compared with the DC group (47.9% vs 29.2%, p = 0.04). Similarly, clinical cure and microbiological eradication were significantly higher when DC was used in patients infected with CR-Kp strains resistant to colistin (13/20 (65%) vs 10/32 (31.3%), p = 0.03 and 11/19 (57.9%) vs 7/27 (25.9%), p = 0.04, respectively). In the logistic regression and multivariate Cox-regression models, the DC regimen was associated with a reduction in 28-day mortality (OR 0.33, 95% CI 0.13-0.87 and OR 0.43, 95% CI 0.23-0.79, respectively). Conclusions: Improved 28-day mortality was associated with the DC regimen compared with ST for severe CR-Kp infections. A randomized trial is needed to confirm these observational results. Trial registration: ClinicalTrials.gov NCT03094494. Registered 28 March 2017.

KW - Critically ill patients

KW - Double carbapenem

KW - Ertapenem

KW - Infections

KW - Klebsiella pneumoniae

KW - Meropenem

KW - Multidrug-resistant bacteria

UR - http://www.scopus.com/inward/record.url?scp=85021714018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021714018&partnerID=8YFLogxK

U2 - 10.1186/s13054-017-1769-z

DO - 10.1186/s13054-017-1769-z

M3 - Article

AN - SCOPUS:85021714018

VL - 21

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 1

M1 - 173

ER -